United States - English - NLM (National Library of Medicine)

marksans pharma limited - ibuprofen (unii: wk2xyi10qm) (ibuprofen - unii:wk2xyi10qm) - ibuprofen 400 mg - carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see  warnings  ). ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. ibuprofen tablets are indicated for relief of mild to moderate pain. ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen. ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see  warnings  ,  anap

Kenya - English - Pharmacy and Poisons Board

marksans pharma limited marksans pharma ltd., bldg.no.37. 111, 1st floor, - terbinafine hydrochloride - tablet - 250mg - antifungals for systemic use

Bangladesh - English - DGDA (Directorate General of Drug Administration)

a h pharmaceuticals (ay) - dashan sanskar churna - powder

Bangladesh - English - DGDA (Directorate General of Drug Administration)

bangladesh pharmaceuticls (ayurvedic) - dashan sanskar churna - powder

Bangladesh - English - DGDA (Directorate General of Drug Administration)

jain pharmaceuticals (ay) - dashan sanskar churna - semi-solid

Bangladesh - English - DGDA (Directorate General of Drug Administration)

mohamaya aushadhalaya (ay) - dashan sanskar churna - powder

Bangladesh - English - DGDA (Directorate General of Drug Administration)

rajendra aushadhalaya (pvt.) ltd. (ay) - dashan sanskar churna - powder

Bangladesh - English - DGDA (Directorate General of Drug Administration)

shabeshree aushadhalaya ayurvedic - dashan sanskar churna - powder

United States - English - NLM (National Library of Medicine)

marksans pharma limited - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen 250 mg - naproxen tablets are indicated for: the relief of the signs and symptoms of: ·         rheumatoid arthritis ·         osteoarthritis ·         ankylosing spondylitis ·         polyarticular juvenile idiopathic arthritis ·         tendonitis ·         bursitis ·         acute gout the management of ·         pain ·         primary dysmenorrhea naproxen tablets are contraindicated in the following patients: •  known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9)] •  history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] •  in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)] risk summary   use of nsaids, including naproxen tablets, can cause premature closure of the feta

United States - English - NLM (National Library of Medicine)

marksans pharma limited - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine delayed-release capsules are indicated for the treatment of: • major depressive disorder in adults • generalized anxiety disorder in adults and pediatric patients 7 years of age and older • diabetic peripheral neuropathic pain in adults • fibromyalgia in adults and pediatric patients 13 years of age and older • chronic musculoskeletal pain in adults the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administration (2.8)and warnings and precautions (5.4)].   starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increa